Role of the Interaction of Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors 1 and 2 in Bone-Related Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Feb 15

PMID 35163403

Authors

Hideki Kitaura

Aseel Marahleh

Fumitoshi Ohori

Takahiro Noguchi

Yasuhiko Nara

Adya Pramusita

Ria Kinjo

Jinghan Ma

Kayoko Kanou

Itaru Mizoguchi

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor-α (TNF-α) is a pleiotropic cytokine expressed by macrophages, monocytes, and T cells, and its expression is triggered by the immune system in response to pathogens and their products, such as endotoxins. TNF-α plays an important role in host defense by inducing inflammatory reactions such as phagocytes and cytocidal systems activation. TNF-α also plays an important role in bone metabolism and is associated with inflammatory bone diseases. TNF-α binds to two cell surface receptors, the 55kDa TNF receptor-1 (TNFR1) and the 75kDa TNF receptor-2 (TNFR2). Bone is in a constant state of turnover; it is continuously degraded and built via the process of bone remodeling, which results from the regulated balance between bone-resorbing osteoclasts, bone-forming osteoblasts, and the mechanosensory cell type osteocytes. Precise interactions between these cells maintain skeletal homeostasis. Studies have shown that TNF-α affects bone-related cells via TNFRs. Signaling through either receptor results in different outcomes in different cell types as well as in the same cell type. This review summarizes and discusses current research on the TNF-α and TNFR interaction and its role in bone-related cells.

Citing Articles

Exploring the Osteoinductive Potential of Bacterial Pyomelanin Derived from in a Human Osteoblast Model.

Urbaniak M, Rudnicka K, Plocinski P, Chmiela M Int J Mol Sci. 2025; 25(24.

PMID: 39769171 PMC: 11678243. DOI: 10.3390/ijms252413406.

Pathogenesis and research progress of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Shan G, Wan H, Zhang Y, Cheng J, Qiao D, Liu Y World J Hepatol. 2024; 16(10):1142-1150.

PMID: 39474575 PMC: 11514618. DOI: 10.4254/wjh.v16.i10.1142.

Mechanistic Exploration of Roxb. in Osteoarthritis: Insights from Network Pharmacology, Molecular Docking, and In Vitro Validation.

Ilyas S, Baek C, Manan A, Choi Y, Jo H, Lee D Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458926 PMC: 11510151. DOI: 10.3390/ph17101285.

The role of cytokines in the pathogenesis of SAPHO syndrome.

Yang Y, Chen Q, Zhong W Front Immunol. 2024; 15:1427784.

PMID: 39286247 PMC: 11402674. DOI: 10.3389/fimmu.2024.1427784.

The ability of microRNAs to regulate the immune response in ischemia/reperfusion inflammatory pathways.

Artimovic P, Spakova I, Macejkova E, Pribulova T, Rabajdova M, Marekova M Genes Immun. 2024; 25(4):277-296.

PMID: 38909168 PMC: 11327111. DOI: 10.1038/s41435-024-00283-6.

References

Nakashima K, de Crombrugghe B . Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet. 2003; 19(8):458-66. DOI: 10.1016/S0168-9525(03)00176-8. View

Jupp O, McFarlane S, Anderson H, Littlejohn A, Mohamed A, MACKAY R . Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. Biochem J. 2001; 359(Pt 3):525-35. PMC: 1222173. DOI: 10.1042/0264-6021:3590525. View

Gerstenfeld L, Cho T, Kon T, Aizawa T, Cruceta J, Graves B . Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs. 2001; 169(3):285-94. DOI: 10.1159/000047893. View

Kohara H, Kitaura H, Fujimura Y, Yoshimatsu M, Morita Y, Eguchi T . IFN-γ directly inhibits TNF-α-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions. Immunol Lett. 2011; 137(1-2):53-61. DOI: 10.1016/j.imlet.2011.02.017. View

Ito N, Wijenayaka A, Prideaux M, Kogawa M, Ormsby R, Evdokiou A . Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol Cell Endocrinol. 2014; 399:208-18. DOI: 10.1016/j.mce.2014.10.007. View

Otto F, Thornell A, Crompton T, Denzel A, Gilmour K, Rosewell I . Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997; 89(5):765-71. DOI: 10.1016/s0092-8674(00)80259-7. View

Lacey D, Simmons P, Graves S, Hamilton J . Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. Osteoarthritis Cartilage. 2009; 17(6):735-42. DOI: 10.1016/j.joca.2008.11.011. View

Ducy P, Zhang R, Geoffroy V, Ridall A, Karsenty G . Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997; 89(5):747-54. DOI: 10.1016/s0092-8674(00)80257-3. View

Tartaglia L, WEBER R, Figari I, Reynolds C, Palladino Jr M, Goeddel D . The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A. 1991; 88(20):9292-6. PMC: 52700. DOI: 10.1073/pnas.88.20.9292. View

10.

Tracey K, Cerami A . Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 1993; 9:317-43. DOI: 10.1146/annurev.cb.09.110193.001533. View

11.

Segueni N, Benmerzoug S, Rose S, Gauthier A, Bourigault M, Reverchon F . Innate myeloid cell TNFR1 mediates first line defence against primary Mycobacterium tuberculosis infection. Sci Rep. 2016; 6:22454. PMC: 4773807. DOI: 10.1038/srep22454. View

12.

Lomaga M, Yeh W, Sarosi I, Duncan G, Furlonger C, Ho A . TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 1999; 13(8):1015-24. PMC: 316636. DOI: 10.1101/gad.13.8.1015. View

13.

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H . Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3(6):889-901. DOI: 10.1016/s1534-5807(02)00369-6. View

14.

Idress M, Milne B, Thompson G, Trembleau L, Jaspars M, Houssen W . Structure-Based Design, Synthesis and Bioactivity of a New Anti-TNFα Cyclopeptide. Molecules. 2020; 25(4). PMC: 7071015. DOI: 10.3390/molecules25040922. View

15.

Marahleh A, Kitaura H, Ohori F, Kishikawa A, Ogawa S, Shen W . TNF-α Directly Enhances Osteocyte RANKL Expression and Promotes Osteoclast Formation. Front Immunol. 2020; 10:2925. PMC: 6923682. DOI: 10.3389/fimmu.2019.02925. View

16.

Tavassoli M, CROSBY W . Transplantation of marrow to extramedullary sites. Science. 1968; 161(3836):54-6. DOI: 10.1126/science.161.3836.54. View

17.

Zhou M, Li S, Pathak J . Pro-inflammatory Cytokines and Osteocytes. Curr Osteoporos Rep. 2019; 17(3):97-104. DOI: 10.1007/s11914-019-00507-z. View

18.

Morita M, Iwasaki R, Sato Y, Kobayashi T, Watanabe R, Oike T . Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis. Sci Rep. 2017; 7:46322. PMC: 5384218. DOI: 10.1038/srep46322. View

19.

Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S . Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000; 191(2):275-86. PMC: 2195746. DOI: 10.1084/jem.191.2.275. View

20.

Tartaglia L, Goeddel D . Two TNF receptors. Immunol Today. 1992; 13(5):151-3. DOI: 10.1016/0167-5699(92)90116-O. View